ClinicalTrials.gg

Glomerulonephritis, IGA clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 276 studies for Glomerulonephritis, IGA across more than 10 countries. 108 are recruiting or about to start. 240 of them are mainly about Glomerulonephritis, IGA (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
94
Recruiting
68
Not yet recruiting
33
Status unknown
29
Active, not recruiting
21
Terminated
16

Phase

Phase 2
83
Phase 3
52
Phase 4
32
Phase 1
25
Early Phase 1
12

Where

China
127
United States
73
United Kingdom
38
Australia
34
Spain
32
France
31

Who develops what

Add Glomerulonephritis, IGA to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 35 programs from 30 companies, 33 with this as their studies’ main aim; 13 with a live phase 3 study; 11 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Novartis and Innovent Biologics here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
IrbesartanRecent, limited
Evidence
  • NCT06635772 · Hansoh Pharmaceutical Group Company Limited · Phase 2 · live · comparator · “Irbesartan” · registered Oct 2024
  • NCT03762850 · Travere Therapeutics, Inc. · Phase 3 · comparator · “irbesartan” · registered Nov 2018
Sanofi56% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 2 generics authorized11 study
sibeprenlimabRecent, limited
Evidence
  • NCT07890909 · Vertex Pharmaceuticals Incorporated · Phase 3 · live · comparator · “Sibeprenlimab” · registered Oct 2026
Otsuka Holdings Co., Ltd.100% of its industry studiesUS: Otsuka Holdings Co., Ltd. (FDA 2025)11 study
telitaciceptRecent, limited
Evidence
  • NCT07522099 · ADARx Pharmaceuticals, Inc. · Phase 2 · live · background · “Telitacicept” · registered Feb 2026
RemeGen Co., Ltd.76% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
diosuxentan☆ Track1 live phase-3 study: NCT06819826Biocity Biopharmaceutics Co., Ltd.
felzartamab☆ Track1 live phase-3 study: NCT06935357Biogen
zigakibart☆ Track2 live phase-3 studies: NCT06858319, NCT05852938Novartis
HRS-5965☆ Track1 live phase-3 study: NCT07014826Jiangsu HengRui Medicine Co., Ltd.
HSK39297☆ Track1 live phase-3 study: NCT07390123Haisco Pharmaceutical Group Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 35 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (11)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 5 Dec 2026 est.HSK39297 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 main aimNCT07616700 A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy — primary endpoint: Incidence and severity of adverse events (AEs) during treatment. · 73 enrolled
  • 29 Dec 2026 est.SGB-9768 · Suzhou Sanegene Bio Inc. · Phase 2 main aimNCT06786338 A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases — primary endpoint: change from baseline in urine protein-creatinine ratio (UPCR) · 45 enrolled
  • 31 Dec 2026 est.diosuxentan · Biocity Biopharmaceutics Co., Ltd. · Phase 3 main aimNCT06819826 A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria — primary endpoint: Change from baseline in 24-hour urine protein-to-creatinine ratio (24h-UPCR) at 36 weeks · 360 enrolled

8 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Glomerulonephritis, IGA studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Endothelin receptor antagonists 6 open · Corticosteroids 4 open · Angiotensin receptor blockers (ARBs) 3 open · Antimetabolites 3

Coming up

32studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger. 21 (31%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (7%) take healthy volunteers.

Recruiting studies that take each age, of 68
AgeWomenMen
1017 (25%)17 (25%)
1867 (99%)67 (99%)
3062 (91%)62 (91%)
4062 (91%)62 (91%)
5061 (90%)61 (90%)
6559 (87%)59 (87%)
7554 (79%)54 (79%)
8543 (63%)43 (63%)

Across all 276 studies, recruiting or not: 48% stop at 75 or younger and 25% at 65; 18% take children; <1% are for women only and 0% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Glomerulonephritis, IGA studies take

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 111 mo4–13 · 22 studies——
Phase 233 mo17–50 · 41 studies——
Phase 355 mo39–70 · 26 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 276. Browse all 276 → or search them.